Affluent Medical becomes Carvolix with two acquisitions

Affluent Medical, a French medical technology company, has announced the upcoming acquisition of Caranx Medical and Artedrone, thus forming Carvolix. This new entity will focus on cardiovascular therapies through innovation in implants and AI-driven autonomous mini-robotics.

The financing for this operation, which does not require any cash outlay, will reach up to 30 million euros. The merger aims to democratize vital medical procedures by using cutting-edge technologies, particularly in heart valve replacement.

Carvolix plans to launch its FDA-approved TAVIPILOT software in the United States in the first quarter of 2026. A general meeting will be held on January 30, 2026, to approve this landmark transaction.